Navigation Links
Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushing's disease patients in Phase III study
Date:3/7/2012

EAST HANOVER, N.J., March 7, 2012 /PRNewswire/ -- A study published in The New England Journal of Medicine (NEJM) found that the investigational drug Signifor® (SOM230, pasireotide), normalized cortisol levels and showed clinical benefit in patients with Cushing's disease(1). This study, which was first presented at the 14th Congress of the European Neuroendocrine Association in September 2010, is the first Phase III trial to demonstrate the efficacy of a medical therapy for Cushing's disease.

Cushing's disease is a debilitating endocrine disorder caused by excess cortisol in the body due to the presence of a non-cancerous pituitary tumor. There are currently no approved medicines that target Cushing's disease(5).

In the study, patients were randomized to receive pasireotide subcutaneous (sc) injection in doses of 900 micrograms or 600 micrograms twice daily. For the 900 microgram group, the study met the primary endpoint of normalizing urinary-free cortisol (UFC) levels, the key measure of biochemical control of the disease. UFC levels were normalized in 26.3% and 14.6% of patients with Cushing's disease randomized to receive pasireotide 900 micrograms and 600 micrograms twice daily, respectively, at six months of treatment. After 12 months of treatment, results confirmed the durability of the effect(1).

"While rare, Cushing's disease is a serious disease with no cure and very limited treatment options," said Annamaria Colao, MD, lead study investigator and Professor of Endocrinology, Chief of the Neuroendocrine Unit at the Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples. "These data on pasireotide are the first to show a therapeutic treatment can help patients achieve biochemical control of their Cushing's disease, while improving associated symptoms."

Study results also showed that cortisol levels decreased quickly in the majority of patients, with a median decreas
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... DIEGO , July 31, 2014  Sorrento Therapeutics, Inc. ... of Mr. Amar Singh , Chief Business Officer and ... apparent natural causes on July 30. "Sorrento is ... friend and colleague. Our immediate thoughts go to Amar,s family ... and Chief Executive Officer. Mr. Singh joined ...
(Date:7/31/2014)... -- ResMed Inc. (NYSE: RMD ) today announced results ... June 30, 2014.  Revenue for the quarter was $415.2 million, ... 1 percent decrease on a constant currency basis). Net income ... the quarter ended June 30, 2013. Diluted earnings per share ... compared to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ) today ... June 30, 2014. Financial Results for the Six ... revenue for the quarter ended June 30, 2014 increased to ... 30, 2013 primarily due to IMBRUVICA ® (ibrutinib) net ... for the six months ended June 30, 2014 increased to ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23
... 2011 Abaxis, Inc. (NasdaqGS: ABAX), a medical products company ... to discuss its financial results for the second quarter of ... be at 4:15 p.m. ET on Tuesday, October 25, 2011. ... of fiscal year 2012 after the market closes on Tuesday, ...
... Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), a specialty ... on Monday, October 31, 2011 before the opening of the ... call that day at 10:00 a.m. ET to discuss results ... to be used during the call will be available on ...
Cached Medicine Technology:Abaxis to Report Second Quarter Fiscal Year 2012 Financial Results Tuesday, October 25, 2011 2Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011 2Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011 3
(Date:8/1/2014)... 2014 Stress management can be difficult in ... of concentration and diminish rest and leisure time, stress can ... critical to find a way to manage stress in order ... , “Having a good sense of work-life balance is the ... founding clinician of SF Custom Chiropractic. “Stress, left unchecked, ...
(Date:8/1/2014)... Register to join the webinar here: http://bit.ly/1lPZNI9 . ... record for life sciences investing. IPOs in the sector tripled ... all venture dollars spent in 2013. The result: biotech companies ... However, 2014 is proving more of a mixed bag of ... while life sciences IPOs are losing steam, M&A is expected ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Just in ... Duke’s Chowder House is featuring new summertime drink ... all six Duke’s locations throughout the season. ... guests alike, Duke’s award-winning, customer-nominated Seattle’s best happy hour ... To celebrate its Lake Union location’s 25th anniversary this ...
(Date:7/31/2014)... San Francisco, California (PRWEB) July 31, 2014 ... 1960s Grateful Dead Psychedelic Acid Test concert posters. Owsley ... bolt skull logo for the Grateful Dead. According to ... Ken Kesey to promote acid test parties in San ... test posters were printed on three different colors of ...
(Date:7/31/2014)... 2014) If you have asthma, you may have an ... you recognize and respond to changes and understand when symptoms ... the green zone, you,re doing well, yellow means your asthma ... require urgent care. New guidelines are now available to help ... into green and away from the red zone. , "Management ...
Breaking Medicine News(10 mins):Health News:SF Custom Chiropractic Celebrates National Relaxation Day and the Benefits of Massage Therapy for the Month of August 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 2Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 3
... effective, a new review of studies has found. Not ... depression and health-related quality of life, they also reduce ... analysis was both more inclusive and more conservative than ... that these interventions are helpful,” said psychologist and review ...
... last year, Soraya Kohanzadeh, 30, Muir Beach, CA, was ... and expecting to live a shortened life// dependent on ... her “anti-donor” antibody levels were so high, her doctors ... ever. However, thanks to a specialized type of anti-rejection ...
... Merck and Co., hopes to offer Gardasil, to developing countries ... the only vaccine against Human Papilloma Virus, that is insinuated ... Statistics reveal that cervical cancer is rampant in developing countries.80% ... in developing nations. ,A single dose of Gardasil ...
... method to identify deposits in brain seen in people ... this disorder suffer mostly in their cognitive abilities and ... be able to distinguish people who may develop Alzheimer's ... extent .Nearly 5 million people in the USA are ...
... Medicine have pinpointed a key regulatory protein that translates ... in a model of mouse embryonic development a transcription ... blood vessels, is activated by rapid, pulsed blood flow, ... Understanding Klf2’s role in blood vessel and muscle biology ...
... their collaborators are gaining widespread attention for discoveries involving ... to AIDS patients. Their findings about Toxoplasma gondii and ... Nature published a paper Wednesday, Dec. 20, in its ... 15 and PLoS Pathogens on Oct. 27. ...
Cached Medicine News:Health News:Psychological Treatments Improve Outcomes for Back Pain Sufferers 2Health News:Psychological Treatments Improve Outcomes for Back Pain Sufferers 3Health News:Therapy Modulates Highly Sensitized Immune System to Let Mother Give Kidney to Daughter 2Health News:Therapy Modulates Highly Sensitized Immune System to Let Mother Give Kidney to Daughter 3Health News:Therapy Modulates Highly Sensitized Immune System to Let Mother Give Kidney to Daughter 4Health News:Novel Brain Scan to Diagnose Alzheimer's Disease 2Health News:Novel Brain Scan to Diagnose Alzheimer's Disease 3Health News:How Blood Flow Dictates Gene Expression 2Health News:New Findings on Toxoplasmosis 2Health News:New Findings on Toxoplasmosis 3
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
Medicine Products: